EUS-Guided Gastroenterostomy Beats Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: Randomised Trial Shows Faster Diet, Shorter Stay and Lower Costs
Posted inGastroenterology General Surgery news

EUS-Guided Gastroenterostomy Beats Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: Randomised Trial Shows Faster Diet, Shorter Stay and Lower Costs

A multicentre randomized trial (NCT05548114) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction, with faster return to solid diet, shorter hospitalisation, better quality-of-life and lower costs.
CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction
Posted inGastroenterology news Oncology

CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction

Large clinical and functional study shows CTNNA1-truncating variants cause loss of αE-catenin via nonsense-mediated decay, confer substantially elevated risks of diffuse gastric cancer and lobular breast cancer versus general population but are less penetrant than CDH1 mutations; proposes simplified testing ('Porto' criteria) and clinical implications.
Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps
Posted inGastroenterology news

Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps

A multicentre French ESD registry found that, after adjusting for size and morphology, large non‑pedunculated rectal polyps do not have higher rates of submucosal invasive cancer than equivalent colonic lesions; technical outcomes of ESD were comparable, with a trend to higher complications in the colon.
PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade
Posted inGastroenterology news Oncology

PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade

Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 blockade restores antitumour immunity in preclinical models, supporting biomarker‑driven combination trials.
Peginterferon Add‑On to siRNA JNJ‑73763989 Yields Deep HBsAg Declines but Not Durable Off‑Therapy Cure in HBeAg‑Positive CHB: Phase 2 REEF‑IT Results
Posted inGastroenterology Infectious Diseases news

Peginterferon Add‑On to siRNA JNJ‑73763989 Yields Deep HBsAg Declines but Not Durable Off‑Therapy Cure in HBeAg‑Positive CHB: Phase 2 REEF‑IT Results

In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained off‑therapy HBsAg loss endpoint at 24 weeks.
Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk
Posted inGastroenterology Infectious Diseases news

Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk

A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subgroups that may benefit from earlier antiviral therapy and intensified surveillance.
Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
Posted inGastroenterology news Oncology Transplantation

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors

A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI washout, and younger recipient age were independent predictors.
Predicting Early Acute Kidney Injury After Liver Transplantation: A Clinically Useful 48‑Hour Risk Model
Posted inGastroenterology Nephrology news Transplantation

Predicting Early Acute Kidney Injury After Liver Transplantation: A Clinically Useful 48‑Hour Risk Model

A single-center study developed and internally validated a 48‑hour post‑liver transplant AKI risk model using five readily available preoperative and intraoperative variables (HE, alcohol cirrhosis, ALBI ≥ −1.78, operation time ≥560 min, and FFP transfusion). The model showed good discrimination (AUC ≈0.76).
Higher Early IV Fluid Rates Tied to More SIRS but Lower BUN Rise in Acute Pancreatitis: Findings From an International Cohort Presented at ACG 2025
Posted inCritical Care Gastroenterology news

Higher Early IV Fluid Rates Tied to More SIRS but Lower BUN Rise in Acute Pancreatitis: Findings From an International Cohort Presented at ACG 2025

An international prospective cohort found that higher early IV fluid rates were associated with lower odds of BUN rise but higher odds of new or persistent SIRS at 6 and 24 hours after presentation, highlighting confounding issues and the need to individualize resuscitation.